Loading...

By Anmol Motwani - Thu, 12/12/2024 - 10:11

COFEPRIS approves LEQEMBI for Alzheimer’s, diabetes rises, Klebsiella oxytoca outbreak, and calls for higher tobacco taxes to curb smoking rates.

Partnership Content

https://mexicobusiness.news/tag/leqembi

More Health

By Sofía Garduño - Thu, 12/05/2024 - 12:06

COFEPRIS approves LEQEMBI for early Alzheimer’s disease, which reduces disease progression and cognitive decline.

By MBN Staff - Wed, 07/31/2024 - 17:22

Leqembi's data shows a 31% reduction in cognitive decline, with no new safety issues, contrasting with Lilly’s Kisunla in cost and approach.

By MBN Staff - Thu, 07/04/2024 - 09:59

The FDA approves Eli Lilly's Alzheimer's drug Kisunla, marking a significant advance in treatment options for early-stage Alzheimer's patients.